S10OD040131
Project Grant
Overview
Grant Description
VisualSonics Vevo F2 LAZR-X20 Photoacoustic and Ultrasound Imaging System - This proposal requests NIH funding for the procurement of a VisualSonics Vevo F2 LAZR X20 multi-modal imaging system.
The Vevo F2 LAZR X20 is a highly versatile imaging system specifically designed for non-invasive pre-clinical small animal research.
This newer generation ultrasound/photoacoustic imager will replace the old generation Vevo 2100 LAZR system that has been phased out by Fujifilm VisualSonics.
The new equipment will enable high resolution longitudinal investigation of anatomical and functional changes associated with disease progression and enable monitoring of therapeutic responses in a non-invasive manner.
The instrument will support 8 major users, 5 minor users and 4 early-career investigators at the Massachusetts General Hospital’s Wellman Center for Photomedicine (Dermatology and Pathology), Neurosurgery, Cardiovascular Research Center (Medicine), and Athinoula A. Martinos Center for Biomedical Imaging.
The diverse research applications of these researchers are focused on using imaging technology to understand the pathophysiology of an array of high impact diseases such as cancer, cardiovascular disease, abnormal brain function, neurological pathologies/injury, and antibiotic-resistant infections.
Collectively, these scientists have experience using the most sophisticated optical imaging technologies currently available to biomedical research, each of which has its own intrinsic strengths and weaknesses.
An internal advisory committee formed will ensure smooth operations, training, maintenance, compliance and resolve user time conflicts.
A strong institutional and departmental support will ensure maintenance, support for core staff and other technical staff and a provision for training new research staff.
There is no accessible photoacoustic system available to us where animals can be easily transported for any of the above applications.
There are just two existing US/PAI systems in the Boston area – Vevo 3100 LAZR-X.
However, the sales of this model has been discontinued by the vendor with official support ending in 2027, further limiting their ability to sustain or expand access for new users.
This will be the first Vevo F2 LAZR X20 system in Boston.
A few unique features of the new Vevo F2 LAZR X20 system are listed below:
• An increased wavelength range (660-1320 nm) with increased laser power enabling photoacoustic imaging for treatment planning and monitoring at a depth not obtainable with other optical imaging technologies
• Capability to customize configuration (waveforms and pulse sequences) for acoustic engineering
• Real-time display of co-registered physiological and anatomical information of target tissues
• Capability to perform 4D and whole-body imaging
• Measure tissue oxygenation and hemodynamics
• Monitoring physiological and anatomical changes in high resolution
The Vevo F2 LAZR X20 is a highly versatile imaging system specifically designed for non-invasive pre-clinical small animal research.
This newer generation ultrasound/photoacoustic imager will replace the old generation Vevo 2100 LAZR system that has been phased out by Fujifilm VisualSonics.
The new equipment will enable high resolution longitudinal investigation of anatomical and functional changes associated with disease progression and enable monitoring of therapeutic responses in a non-invasive manner.
The instrument will support 8 major users, 5 minor users and 4 early-career investigators at the Massachusetts General Hospital’s Wellman Center for Photomedicine (Dermatology and Pathology), Neurosurgery, Cardiovascular Research Center (Medicine), and Athinoula A. Martinos Center for Biomedical Imaging.
The diverse research applications of these researchers are focused on using imaging technology to understand the pathophysiology of an array of high impact diseases such as cancer, cardiovascular disease, abnormal brain function, neurological pathologies/injury, and antibiotic-resistant infections.
Collectively, these scientists have experience using the most sophisticated optical imaging technologies currently available to biomedical research, each of which has its own intrinsic strengths and weaknesses.
An internal advisory committee formed will ensure smooth operations, training, maintenance, compliance and resolve user time conflicts.
A strong institutional and departmental support will ensure maintenance, support for core staff and other technical staff and a provision for training new research staff.
There is no accessible photoacoustic system available to us where animals can be easily transported for any of the above applications.
There are just two existing US/PAI systems in the Boston area – Vevo 3100 LAZR-X.
However, the sales of this model has been discontinued by the vendor with official support ending in 2027, further limiting their ability to sustain or expand access for new users.
This will be the first Vevo F2 LAZR X20 system in Boston.
A few unique features of the new Vevo F2 LAZR X20 system are listed below:
• An increased wavelength range (660-1320 nm) with increased laser power enabling photoacoustic imaging for treatment planning and monitoring at a depth not obtainable with other optical imaging technologies
• Capability to customize configuration (waveforms and pulse sequences) for acoustic engineering
• Real-time display of co-registered physiological and anatomical information of target tissues
• Capability to perform 4D and whole-body imaging
• Measure tissue oxygenation and hemodynamics
• Monitoring physiological and anatomical changes in high resolution
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding Agency
Place of Performance
Boston,
Massachusetts
021142621
United States
Geographic Scope
Single Zip Code
The General Hospital Corporation was awarded
Project Grant S10OD040131
worth $1,061,520
from the National Institute of Allergy and Infectious Diseases in May 2026 with work to be completed primarily in Boston Massachusetts United States.
The grant
has a duration of 1 year and
was awarded through assistance program 93.351 Research Infrastructure Programs.
The Project Grant was awarded through grant opportunity High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 5/21/26
Period of Performance
5/1/26
Start Date
4/30/27
End Date
Funding Split
$1.1M
Federal Obligation
$0.0
Non-Federal Obligation
$1.1M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
S10OD040131
SAI Number
S10OD040131-670536676
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75AGNA NIH AGGREGATE FINANCIAL ASSISTANCE DATA AWARDING OFFICE
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
FLJ7DQKLL226
Awardee CAGE
0ULU5
Performance District
MA-08
Senators
Edward Markey
Elizabeth Warren
Elizabeth Warren
Modified: 5/21/26